A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
Public ClinicalTrials.gov record NCT03292406. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Multi-centre, Placebo-controlled, Parallel-arm Phase 2 Trial to Assess Safety, Efficacy and Pharmacokinetics of CD11301 0.03% and 0.06% Gel in the Treatment of Cutaneous T-Cell Lymphoma (CTCL), Stages IA, IB and IIA
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess the efficacy, safety and pharmacokinetics in participants treated with CD11301 gel vs. placebo for early stage CTCL (IA, IB, or IIA).
Study identification
- NCT ID
- NCT03292406
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 86 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 19, 2017 (Actual)
- Primary completion
- Mar 17, 2020 (Actual)
- Completion
- Mar 17, 2020 (Actual)
- Last update posted
- Apr 8, 2021
2017 – 2020
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Galderma Investigational Site | Orange | California | 92868 | — |
| Galderma Investigational Site | Palo Alto | California | 94304 | — |
| Galderma Investigational Site | Farmington | Connecticut | 06032 | — |
| Galderma Investigational Site | Chicago | Illinois | 60611 | — |
| Galderma Investigational Site | Boston | Massachusetts | 02115 | — |
| Galderma Investigational Site | Durham | North Carolina | 27710 | — |
| Galderma Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Galderma Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| Galderma Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| Galderma Investigational Site | Dallas | Texas | 75231 | — |
| Galderma Investigational Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03292406, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 8, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03292406 live on ClinicalTrials.gov.